REGENXBIO Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from REGENXBIO Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 51% in 3 years; of every extra $100 of sales, $150 became extra profit. Higher than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-34.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 67% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 3/3Sales grew in 1 of the last 3 years; profit grew in 3 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$150Sales grew 51% in 3 years; of every extra $100 of sales, $150 became extra profit.
Higher than 85% of Healthcare companies in United States.
Asset Productivity Ratio
+51% / -46%In 3 years sales changed by +51% while total assets changed by -46%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-15.0×Operating cash was negative last year, while some debt falls due within a year.
Higher than 50% of Healthcare companies in United States.
Cash Cushion Ratio
+33%Cash, after subtracting all debt, equals 33% of its market value (net cash).
Higher than 70% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
REGENXBIO Inc. made a loss over the last year. REGENXBIO Inc. owes $0.81 for every $1 it owns. REGENXBIO Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossREGENXBIO Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
6.60The share price is 6.60 times REGENXBIO Inc.'s book value per share, higher than 78% of Healthcare companies in United States.
Market cap
$473 MThe total market value of all of REGENXBIO Inc.'s shares at today's price (share price × number of shares), larger than 54% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$72 MWhat REGENXBIO Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.09Net worth divided by the number of shares. The share price of $7.17 is 6.6 times this, which is the P/B above.
Return on equity (ROE)
-137.6%REGENXBIO Inc. lost 137.6% of its shareholders' money over the last year, lower than 78% of Healthcare companies in United States.
Owes vs Owns
0.81×REGENXBIO Inc. owes $0.81 for every $1 it owns (high), higher than 79% of Healthcare companies in United States.
Dividend yield
NoneREGENXBIO Inc. does not currently pay a dividend.
Revenue growth
+105%Revenue rose 105% in the year to Dec 2025, and grew 15% a year on average over 3 years.
Profit growth
LossREGENXBIO Inc. made a loss in each of the last two years.
Profit margin
-113.8%REGENXBIO Inc. lost $114 for every $100 of revenue.
Interest cover
Not coveredREGENXBIO Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashREGENXBIO Inc. held $157 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For REGENXBIO Inc.: $473 M ÷ $72 M (30 Jun 2026) = 6.6.
What is REGENXBIO Inc.'s return on equity?
REGENXBIO Inc. lost 137.6% of its shareholders' money over the last year, lower than 78% of Healthcare companies in United States.
How much does REGENXBIO Inc. owe compared with what it owns?
REGENXBIO Inc. owes $0.81 for every $1 it owns (high), higher than 79% of Healthcare companies in United States.
Does REGENXBIO Inc. pay a dividend?
No. REGENXBIO Inc. does not currently pay a dividend.
Is REGENXBIO Inc.'s revenue growing?
Revenue rose 105% in the year to Dec 2025, and grew 15% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.